Trial Profile
A Phase 1 Study of LY2624587 in Patients With Advanced Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2012
Price :
$35
*
At a glance
- Drugs LY 2624587 (Primary)
- Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
- Focus Adverse reactions
- 23 Jan 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 23 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.